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Abstract. Hyperprolactinaemia is one of the major causes of reproductive axis disorders. Adequate treatment for 
hyperprolactinaemia is very successful in restoring ovulation, but there is still a proportion of patients unable to 
achieve pregnancy despite adequate control of hyperprolactinaemia. This prospective clinical trial included 104 
hyperprolactinaemic patients in reproductive age: 78/104 (75%) suffered from infertility and the other 26 
hyperprolactinaemic patients were still unmarried and not interested in pregnancy. Hyperpolactinaemia as the only 
reason for anovulation and infertility was diagnosed in 43/78 (55.12%) of our patients. In 35/78 (44.88%) patients, 
hyperprolactinaemia was associated with other causes of infertility: endometriosis, premature ovarian failure, PCO 
and insulin resistance, etc. After the appropriate treatment, mostly with bromocriptine (in 69/78 – 88.46%, alone or in 
combination with induction of ovulation), 35/78 (44.87%) patients achieved pregnancy. In the group of infertile 
patients with hyperolactinaemia as the only cause of infertility, 33/43 (76.74%) patients became pregnant, and in the 
group of patients who had combination of hyperprolactinaemia and other causes of infertility only 2/35 (5.71%) 
achieved pregnancy.  The treatment of hyperprolactinaemia is obligatory in all patients with infertility. If adequate 
suppression of serum prolactin levels is achieved, but the pregnancy is still missing despite the fact that ovulatory 
cycles are established, the other causes of infertility should be searched for, and the clinician should not reject the 
possible existence of some unknown cause of infertility, so the patient should be referred to ART procedures which 
give more chances in such circumstances. 
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Introduction

 
Hyperprolactinaemia is one of the major causes of 
reproductive axis disorders, being the major cause of 
hypogonadotropic anovulation and is one of the leading 
causes of infertility in women aged 25–34 [1–4]. Adequate 
treatment for hyperprolactinaemia is very successful in 
restoring ovulation. Nevertheless there is still a proportion 
of patients unable to achieve pregnancy despite adequate 
control of hyperpolactinaemia.  
The aim of this article is to present the association 
between hyperprolactinaemia and other causes of 
female infertility, the combination which could be 
resistant to infertility treatment. 
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Material and Methods 
This prospective clinical trial included 104 
hyperprolactinaemic patients in reproductive age. The 
diagnosis of hyperprolactinaemia was established by single 
measurements of serum prolactine levels in two separate 
occasions (at least two hours before or after sleeping). The 
serum was obtained without excessive venipuncture stress 
and a level higher than upper limit confirmed the diagnosis 
(> 530 mIU/l according to World Health Organization 
Standard 84/500), as it was previously described [3, 5, 6].  
All hyperprolactinaemic patients referred to our 
Clinic were subjects of clinical investigation: anamnesis, 
clinical exam, pelvic ultrasound examination, urine and 
blood analyses (blood picture, biochemical parameters 
including parameters of hepatic and renal function, 
hormonal analysis). The patients with secondary 
hyperprolactinaemia (due to medicaments, hypothyreosis, 
renal or hepatic failure, etc.) were excluded from further 
investigation. The other 104 hyperprolactinaemic patients 
were included in this investigation. Transvaginal 
ultrasound (TVUS) measurements of follicle diameters 
were performed during menstrual cycle in patients with 
regular cycles. At day 2–4 of spontaneous menstrual 
cycle serum levels of follicle-stimulating hormone 
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(FSH), luteinizing hormone (LH), prolactin (PRL), 
oestradiol (Es), progesterone (Pr) and testosterone (Ts) 
were measured and in the middle of luteal phase (day 
22) serum levels of Pr and PRL were measured as well. 
Ovulation was confirmed by adequate development of 
dominate follicle, appearance of corpus luteum on 
TVUS examination and serum progesterone levels 
> 5 ng/ml (16 nmol/l) in the middle of luteal phase (day 
22), as it was described previously [7, 8]. Pituitary MR 
was performed in all hyperprolactinaemic patients with 
serum prolactin levels higher than 2000 mIU/l, as well 
in cases with disproportion of serum prolactin level and 
severity of clinical findings (e.g. prolactin < 2000 mIU/l 
and long lasting amenorrhoea). In patients with 
headaches and visual disturbances pituitary MR was also 
performed. Visus, perimetria and examination of fundus 
oculi were performed in patients with microprolatinomas 
and headaches.  
Infertile patients were also subjects of infertility 
investigation: hysterosalpingography or sonohysterosal-
pyngography, analysis for related infections, laparoscopy 
and hysteroscopy where indicated, etc. Husband’s 
semen analyses were performed too. The effects of 
therapy for hyperprolactinaemia were evaluated at first 
checkup, at the 45th day of the therapy and after 3, 6 
and 12 months of therapy. If the pregnancy was missing 
after 6–9 months from the beginning of the therapy for 
hyperprolactinaemia and normalization of serum prolactin 
levels, induction of ovulation was started parallel with 
therapy for hyperprolactinaemia or patient was referred 
to ART (assisted reproductive technology) procedures 
(which had been already done in infertile couples with 
mechanical infertility or male factor and other 
indications for ART). Patients who achieved pregnancy 
were controlled and delivered at our Clinic. 
Data were processed and statistical analyses were 
performed using commercial software. Statistical 
significance was tested with Student’s t-test (p<0.05 was 
considered as statistically significant) and t-test for 
proportions for small independent samples with Cochran 
and Cox’s corrective approximate method for small 
independent samples was performed where needed. 
Results 
Clinical characteristics of all patients included in this 
prospective clinical investigation are shown in Table 1. 
Clinical characteristics of infertile hyperprolactinaemic 
patients (78/104 or 75%) are shown in Table 2. The 
other 26 hyperprolactinaemic patients were still 
unmarried and not interested in pregnancy, referred to 
our Clinic due to cycle irregularity, galactorrhoea or 
alopecia and hirsutism. 
Serum prolactin levels were higher in amenorrhoeic 
infertile patients in comparison with serum prolactin 
levels in patients with oligomenorrhoea (1489.44± 
388.19 mIU/l; p=0.025463). There were no significant 
differences regarding age and duration of infertility 
between hyperolactinaemic infertile patients with 
amenorrhoea, oligomenorrhoea and regular cycles, with 
exception of statistically significant younger age of 
oligomenorrhoeic patients in comparison with age of the 
patients with normal cycles (Table 3 and 4).  
Table 1. Clinical characteristics of all hyperprolactinaemic 
patients (n=104). 
Age (years)  29.96 ± 5.81 
Cycle irregularity 60/104 (57.69%) 
‒ amenorrhoea 30/104 (28.84%) 
‒ oligomenorrhoea 30/104 (28.84%) 
Regular cycle 44/104 (42.31%) 
Galactorrhoea 12/104 (11.53%) 
Infertility 78/104 (75.00%) 
Hirsutism 13/104 (12.50%) 
Alopecia 6/104 (5.76%) 
Premature ovarian failure 3/104 (2.88%) 
Macroprolactinoma 1/104 (0.96%)  
Microprolactinoma 11/104 (10.57%) 
Enlargement of sella turcica 1/104 (0.96%) 
Anovulatory cycles 76/104 (73.07%) 
Ovulatory cycles 28/104 (26.93%) 
‒ inadequate luteal phase  11/28 (39.29%)  
or 11/104 (10.57%) 
‒ adequate luteal phase  17/28 (60.71%)  
or 17/104 (16.35%) 
Table 2. Clinical characteristics of hyperprolactinaemic 
patients with infertility (n=78) 
Age (years)  30.55 ± 5.22 
Duration of infertility (years)  4.56 ± 2.86 
Primary infertility 67/78 (85.89%) 
Secondary infertility 11/78 (14.11%) 
Amenorrhoea 21/78 (26.92%) 
Oligomenorrhoea 30/78 (38.46%) 
Regular cycles 27/78 (34.61%) 
Galactorrhoea 8/78 (10.25%) 
Table 3. Age of hyperolactinaemic patients with infertility 
 
1. Patients  
with 
amenorrhoea 
n=21 
2. Patients  
with 
oligomenorrhoea 
n=30 
3. Patients 
with  
regular cycles 
n=27 
Age (years) 
X ± SD 
32.0 ± 5.61 28.06 ± 3.61 31.83 ± 3.79 
t-test for 1 and 2 p=0.052944; t-test for 1 and 3 p=0.924765; t-test 
for 2 and 3 p=0.04001 
Table 4. Duration of infertility in patients with hyperpro-
lactinaemia 
 1. Patients  
with 
amenorrhoea 
n=21 
2. Patients  
with 
oligomenorrhoea 
n=30 
3. Patients  
with 
regular cycles 
n=27 
Duration of 
infertility 
(years) 
X ± SD 
4.42 ± 3.35 3.33 ± 1.32 4.8 ± 2.39 
t-test for 1 and 2 p=0.440426; t-test for 1 and 3 p=0.768643; t-test 
for 2 and 3 p=0.067 
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Hyperolactinaemia is relatively often associated with 
other possible causes of infertility — in 35/78 (44.88%) 
patients (Table 5). 
Table 5. Association of hyperprolactinaemia and other 
causes of infertility in our patients 
Male factor 6/78 (7.69%) 
Mechanical factor 4/78 (5.12%) 
Endometriosis 5/78 (6.41) 
Premature ovarian failure 3/78 (3.85%) 
Chlamydia 3/78 (3.85%) 
Asherman’s syndrome 1/78 (1.31%) 
Endometrial polyp 4/78 (5.12%) 
Myoma 7/78 (8.97%) 
Insulin resistance 2/78 (2.56%) 
Hyperpolactinaemia as the only reason for anovulation 
and infertility was diagnosed in 43/78 (55.12%) of our 
patients. This group was separately analyzed. Amenorrhoea 
was present in 20/43 (46.51%), oligomenorrhoea in 12 
(23.53%), and regular cycles in 11/43 (29.96%). 
Anovulatory cycles were present in all patients with 
amenorrhoea and oligomenorrhoea and their serum 
prolactin levels were the highest (Table 6).  
Table 6. Serum prolactin levels in patients with 
hyperrolactinaemia as the only reason for 
infertility 
 
Patients with 
amenorrhoea1 
n=20 
Patients with 
oligomenorrhoea2 
n=12 
Patients with  
regular cycles 3 
n=11 
Serum 
prolactin levels 
(mIU/l) 
X ± SD 
3255.0  
±  
1646.78 
1665.5  
±  
1140.32 
1519.0  
±  
427.53 
t-test for 1 and 2 p=0.03475; t-test for 1 and 3 p=0.033315; t-test 
for 2 and 3 p=0.71 
There were 11 patients with regular cycles and 
elevated serum levels of prolactin as the only diagnosed 
cause for infertility. Inadequate luteal phase was 
diagnosed in 6/11 (54.54%) of those patients according 
to transvaginal ultrasound measurements of follicle 
diameter during menstrual cycle and the mid-cycle 
serum progesterone levels. Serum prolactin levels in 
patients with inadequate luteal phase were higher in 
comparison to serum PRL levels in patients with 
adequate luteal phase (1624.33±369.0 mIU/l vs 1189.33 
±166.63 mIU/l; p=0.03853).  
There were 35 pregnancies in the whole group of 
infertile patients with hyperprolactinaemia (44.87%). 
This proportion of achieved pregnancies is higher in the 
group of patients with hyperprolactinaemia as the only 
cause of infertility —33/43 or 76.74% (Table 7). Two 
patients among them became pregnant again after the 
first delivery with spontaneously normalized serum 
prolactin levels. Table 7 shows the therapy for infertility 
in patients who achieved pregnancy.  
Table 7. Treatment of infertility in patients with 
hyperolactinaemia who achieved pregnancy 
Pregnancy after spontaneous cycles  7/33 (21.21%) 
Bromocriptine only therapy 16/33 (48.49%) 
Bromocriptine + clomiphene 6/33 (18.18%) 
Bromocriptine + clomiphene + HCG + IUI 1/33 (3.03%) 
Quinagolide 2/33 (6.06%) 
Bromocriptine + IVF 1/33 (3.03%) 
HCG, human chorionic gonadotrophine; IUI, intrauterine insemination; 
IVF, in vitro fertilization 
There were only 2/35 (5.71%) patients who achieved 
pregnancy in the group of infertile patients with 
hyperpolactinaemia associated with other causes of 
infertility, which is statistically significantly different 
compared to the group of infertile patients with 
hyperprolactinaemia as the only cause of infertility 
(t=6.27319; p<0.05).  
Cycles in hyperprolactinaemic infertile patients 
treated with bromocriptine became regular after 12.75 ± 
8.68 weeks of the therapy.  
Galactorrhoea ceased after 6.05 ± 0.07 weeks, but 
did not totally disappear in all cases.  
Hyperprolactinaemic patients successfully treated 
for infertility achieved pregnancy after 8.75 ± 3.89 
months of the therapy for hyperprolactinaemia (range 
from 1.5 to 24 months).  
Bromocriptine, alone or in combination with 
clomiphene, was administered in 69/78 (88.46%) 
hyperprolactinaemic infertile patients. In the group of 
infertile patients treated with bromocriptine once a day, 
pregnancy was achieved in 7/34 (20.58%), and if 
bromocriptine was administered 2 or 3 times a day, 17/35 
(48.57%) patients became pregnant (t=2.439964; p<0.05). 
Between these two groups of hyperprolactinaemic patients 
there were no differences in age: (29.0±8.44) years in the 
group with bromocriptine once a day vs. 29.75±7.38 years 
in the group with 2 or 3 daily doses of bromocriptine (t-test 
- p=0.899264); nor in duration of infertility (5.75±2.87 
years vs. 4.25 ±2.5 years; t-test – p=0.408262).  
Bromocriptine therapy was stopped in two patients 
due to visual disturbances. The first patient had visual 
hallucinations (―fire from the electric cooker‖) and the 
second patient experienced scintillations. Another three 
patients switched to quinagolide due to intolerance to 
bromocriptine. In most cases, initial intolerance was 
easily overcome with taking the first dose of bromocriptine 
immediately before sleeping or with gradually increasing 
the bromocriptine dose. 
Outcome of the pregnancies was as follows: 19/35 
were delivered per vias naturalis, with only one preterm 
delivery. Caesarean section was performed in 8/35 
(22.86%) pregnancies. All children were vital and born 
at term, with one exception, born in 34
th
 week, vital. 
After the treatment for hyperprolactinaemia, there were 
5/35 (14.28%) spontaneous abortions, and 3/35 (8.57%) 
missed abortions. 
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Discussion  
In most cases of hyperprolactinaemic infertile patients, 
treatments with control serum prolactin levels can easily 
restore ovulation and the great majority of such patients 
become pregnant. The problem exists in the proportion 
of hyperprolactinaemic patients with combination of 
hyperprolactinaemia and some other causes of infertility. 
Combination of hyperprolactinaemia and endometriosis 
in infertile patient is especially difficult for treatment. 
There are many reports about hyperprolactinaemia in 
patients with endometriosis [9–11], as well as reports 
about positive correlation of serum prolactin levels and 
the stage of endometriosis [12–15]. There is also 
evidence that patients with endometriosis have at least 
occult hyperprolactinaemia, according to TRH (thyrotropin- 
releasing hormone) stimulation, with higher serum 
prolactin levels in patients who had not achieved 
pregnancy during the treatment for endometriosis [12, 
16]. On the other hand, the impact of minimal and mild 
endometriosis to infertility is still unclear [7], even 
though the minimal and mild endometriosis have been 
found during laparoscopy in many infertile patients. The 
infertility in those patients was considered as idiopathic 
until laparoscopy was performed. Unfortunately 
laparoscopy is not a part of routine investigation of 
infertility in some countries [17]. Human decidua produces 
prolactin, and prolactin is considered to be a better 
endometrial marker than prostanoid or CA 125, because 
decidua and endometriotic implants are the only sources 
for prolactin in abdomen, which is not the case with CA 
125, moreover receptors for prolactin are found in 
endometriotic tissue [18]. There is a hypothesis that the 
content of prolactin in peritoneal fluid depends only on 
the activity of endometriotic implants, but there are also 
opposite opinions that the prolactin secretion from those 
implants is negligible, without impact on infertility in 
these patients
 
[19]. It was speculated that prolactin from 
endometriotic implants could be a reason for local ovarian 
dysfunction and inadequate luteal phase which is followed 
by spontaneous abortions. Some studies supported this 
hypothesis [20], and the other authors conclude that the 
endometriosis is associated with inadequate luteal phase, 
but aberrant prolactin secretion by endometriosis implants 
has nothing to do with that [21]. 
Prolactin has immunomodulatory role as up-
regulator of immune processes, and hyperorlactinaemia 
is often present in autoimmune diseases [22]. It is 
possible that immunomodulator characteristics of prolactin 
are connected with association of hyperprolactinaemia and 
endometriosis.  
Nocturnal prolactin peak is exaggerated and prolonged 
in patients with endometriosis [23]. Authors of the study 
concluded that disturbances of nocturnal prolactin 
secretion could contribute to occurrence of infertility in 
patients with endometriosis, and this is the part of 
pathophysiology of that disease. The question is which 
one is the primary: hyperprolactinaemic environment 
which makes individual susceptible to development of 
endometriosis or endometriotic implants that can secrete 
enough amounts of prolactin to cause hyperprolactinaemia 
and subsequent infertility [18]. 
Clinical experience showed that the treatment of 
patients with associated hyperprolactinaemia and 
endometriosis is complicated, and if the success is absent, 
the couple should be referred to IVF as soon as possible.   
The other causes of infertility that could be associated 
with hyperprolactinaemia are premature ovarian failure (in 
5.12% of our patients) and insulin resistance in 
hyperorlactinaemic anovulation (in 2.56% of our patients). 
Even though the proportion is small, those patients still 
deserve attention. Hyperprolactinaemia and polycystic 
ovarian syndrome are different conditions, but insulin 
resistance could be associated with both of them. The 
association of prolactinoma and polycystic ovarian 
syndrome is possible, which has already been reported 
[24]. This is important during the infertility treatment of 
those patients: if the treatment with bromocriptine improves 
insulin resistance, the connection of hyperprlactinaemia and 
insulin resistance is obvious. This was the case with 
both of our hyperprolactinaemic patients with insulin 
resistance, but the small sample precludes us from 
definitive conclusions.  
The relation of hyperprolactinaemia and psychological 
stress due to infertility is a specific question. It is well 
known that elevated prolactin levels are physiological 
correlates of psychosocial stress response. The levels of 
prolactin are higher in emotional than in manipulative 
tears [25]. There are no clinical reports about the impact 
of psychosocial stress caused by infertility to serum 
prolactin levels in hyperprolactinaemic patients, but 
clinical experience showed that empathy, compassion 
and improvement of overall quality of life could improve 
the success of infertility treatment.  
The possible causes of unexplained infertility are 
abnormal function of sperm and oocyte, disorders of 
fertilization, implantation and embryo development 
during early stages. Hyperprolactinaemia could exist 
parallel to such functional disorders, which should be kept 
in mind in cases when the pregnancy was not achieved 
despite of the successful treatment of hyperprolactinaemia, 
so patient should be referred to ART procedures. Yet, 
there is no evidence that hyperprolactinaemia is associated 
with the mentioned abnormalities, possible causes of 
idiopathic infertility. 
The majority of our hyperprolactinaemic patients are 
treated with bromocriptine. In the beginning of the 
therapy, about one half of the patients had nausea and 
vertigo, but these side effects disappeared when the 
medication was taken immediately before going to sleep 
or with gradually increased the doses of bromocriptine. 
Total daily dose of bromocriptine could be divided in 
two or three smaller doses, which offers better control 
of circadian variations of prolactin serum levels, as well 
as better control of nocturnal prolactin levels. The 
majority of our infertile patients with hyperprolactinaemic 
anovulation achieved pregnancy with divided daily 
bromocriptine dose. Visual hallucinations that happened 
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with two of our patients during bromocriptine treatment 
could be explained by the fact that the molecule of 
bromocriptine is similar to molecule of LSD [7]. The 
patients should be warned that their concentration could 
decrease during the bromocriptine treatment, which is 
important for some jobs or during car driving. For patients 
that could not stand side effects of bromocriptine or in 
whom bromocriptine treatment failed the best choice is 
quinagolide [26].  
Quinagolide is equally successful in the treatment of 
hyperprolactinaemia as bromocriptine [27], but there are 
also reports that quinagolide is superior to bromocriptine in 
the treatment of hyperpolactinaemia associated infertility 
[28, 29]. It is better to avoid cabergoline in early 
pregnancy, even though there are reports about its safety, 
we state that patients who desire pregnancy, should switch 
to bromocriptine or quinagolide. Among all dopamine 
agonists, cabergoline has the longest half life (65 hours), 
so it is possible to be administered once or twice a 
week, but also there is a chance for early pregnancy to 
be exposed to the effects of cabergoline. The biggest 
study reported till now has included over 300 cases and 
the incidence of foetal anomalies was not elevated [30]. 
Anyway, further clinical trials are still needed for 
definitive conclusions [31]. Taking into account the effects 
of cabergoline on immunological system and macrophages, 
possible development of cardiac valvulopathy and related 
disorders (pericarditis and pericardial effusion) [29, 32], 
it seems reasonable to avoid this drug in early pregnancy, 
especially that safety of bromocriptine and quinagolide 
in pregnancy is already proven.  
Bromocriptine or quinagolide should be administered 
in hyperprolactinaemic patients who desire the pregnancy 
as long as needed for patient to achieve the pregnancy. In 
our patients with adequate prolactin suppression pregnancy 
was achieved after 8.75±3.89 months of therapy (range 
from 1.5 to 24 months). Bromocriptine is used from 
1971 and till now there were no reported harmful effects 
on early pregnancy and it is considered safe.  
About one fifth of our patients achieved pregnancy 
without the therapy for hyperprolactinaemia which could 
be explained by macroprolactinaemia: hyperolactinaemia 
due to excess macroprolactin with normal concetrations 
of bioactive monomeric prolactin [33]. Macroprolactin 
is composed of macromolecules — isoformes of prolactin 
(dimeric or trimeric molecules; big- and big-big prolactin) 
with little if any biological activity, but readily measured 
by standard assays. It was stated that the screening for 
macroprolactin should be a part of investigation in all 
hyperprolactinaemic patients because it could be a 
significant cause of misdiagnosis and inappropriate 
treatment [33, 34,]. 
Spontaneous abortions were noted as outcome in 
8/35 (22.85%) patients who became pregnant after the 
therapy with bromocriptine, but this proportion was 
similar to the proportion of spontaneous abortions in 
general population. One half of our hyperprolactinaemic 
patients with secondary infertility experienced missed 
abortion before the treatment for hyperprolactinaemia, 
which allows us to make a hypothesis that elevated 
prolactin levels could be a reason, probably not only due 
to inadequate luteal phase or aberrant endometrial 
receptivity, but also due to some still unknown way.  
If the pregnancy passes successfully through the first 
trimester, the outcome is usually the delivery of term 
and viable infant. The other studies have also reported 
that after successfully treating hyperprolactinaemia the 
incidences of spontaneous abortions, ectopic gravidities, 
preterm deliveries and other complications of  pregnancy 
were not elevated [35].  
During the lactation in patients with prolactinomas, 
there were no further growths of tumours [7, 35].  
Spontaneously restored ovulatory cycles have already 
been reported after the delivery of successfully treated 
hyperprolactinaemic patients [7, 35–38]. Similar situation 
has also been noted in our patients: two of them became 
pregnant again without the therapy, year and a half and 
two years after the first delivery. In both of them serum 
prolactin levels were spontaneously normalized, which 
could be explained by pituitary infarcts developed during 
the shrinkage of microprolactinoma in pregnancy or 
spontaneous recovery of hypothalamic dysfunction 
responsible for lactotroph hyperplasia [7]. 
Conclusion  
In one half of the infertile patients with hyperprolactinaemia, 
this is the only cause of infertility and in other half 
hyperprolactinaemia is associated with some other 
causes of female infertility.  
The treatment of hyperprolactinaemia is obligatory in 
all patients with infertility. In our series, bromocriptine 
was successfully used in the majority of patients with 
infertility, with better effects when used in divided 
doses during all day.  
If adequate suppression of serum prolactin levels is 
achieved, but the pregnancy is still missing despite the 
fact that ovulatory cycles are established, other causes 
of infertility should be searched for, and the clinician 
should not reject the possibility of existence of some 
unknown infertility factor, so the patient should be 
referred to assisted reproductive technology procedures 
which provide more chances in such circumstances.  
The treated hyperprolactinaemia has no influence on 
pregnancy outcome. 
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